Therion�s development and manufacturing capabilities, combined with its relationship with national and international research institutions, has enabled it to test multiple protocols and products in human clinical trials, guiding the optimization of the Company�s therapeutic vaccines. To date, its vaccine candidates have been administered in over 30 clinical trials with more than 700 patients treated. The Company�s cancer vaccine development programs are partially supported by a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. Main Page Prostate Cancer Vaccine Pancreatic Cancer Vaccine Collaborations Therion Biologics Corporation develops therapeutic vaccines for cancer and preventive vaccines for AIDS. The Company has two lead programs involving multiple clinical trials: PANVAC-VF� for pancreatic cancer and PROSTVAC-VF� for prostate cancer. Therion is also applying its technology platform to develop vaccines to treat melanoma, breast cancer and other solid tumors. In addition to studies conducted under collaboration with the National Cancer Institute, the Company�s strategic partners include a global network of leading clinical institutions and Aventis Pasteur, Ltd., which is developing ALVAC-CEA/B7.1, a clinical candidate for the treatment of colon cancer. Therion is headquartered in Cambridge, Massachusetts. Back to the top Copyright © Therion Biologics Corporation.